International Journal of Health and Clinical Research
Yazarlar: Nirmal Kumar Rawandale, Jinendra Jain, Pallavi Sapale, Sushant Chavan, Amol D Kinge
Konular:-
Anahtar Kelimeler:Covid 19,Remdesivir,Antiviral,Severe infection,Comorbidities
Özet: Introduction: Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown. We tried to determine the efficacy of 5 or 10 days of remdesivir treatment compared with standard care on clinical status on day 11 after initiation of treatment. Methodology: A retrospective case control study from existing data where we enrolled hospitalized patients with confirmed SARS-CoV-2 infection. . We made two groups of patients. Those who received intravenous remdesivir for either 5 days or 10 days were enrolled as cases. All patients received 200 mg of remdesivir on day 1 and 100 mg once daily on subsequent days. Those who did not received remdesivir as treatment were enrolled as controls. Controls were matched with cases in terms of age, sex and clinical staging at the time of admission. Outcome measures like recovery, death, average time of hospitalization was analysed using proportion and odds ratio at 95% confidence interval using SPSS version 22. Results: 2336 patients were recruited in the study. Recovery rate was found to be positively associated with Remdesivir use (292 (84.63% Odds = 1.75 p value 0.0004). average duration of hospital stay was reduced to 10 days as compared to 15 days in patients who did not received remdesivir. Pateints with comorbidities showed increased recovery (228 (81.13%) odds = 1.86 p value = 0.0001). Deaths among Covid 19 infected patients was negatively assoiated with the use of remdesivir.{53 (15.36%) odds = 0.0580 p value 0.0001}. Conclusion: This study finds treatment of Covid 19 with Remdesivir as an effective method for treatment as the drug has shown to expedite recovery, decreases hospital stay, and decreases death rate among severe Covid 19 infections.